Average Co-Inventor Count = 11.03
ph-index = 7
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Signal Pharmaceuticals, Inc. (13 from 169 patents)
2. Merck + Co., Inc. (5 from 4,770 patents)
3. Celgene Corporation (5 from 549 patents)
4. Merck Sharp + Dohme Corp. (2 from 2,405 patents)
25 patents:
1. 12227490 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith
2. 12103920 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith
3. 11739075 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith
4. 11634407 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith
5. 11560371 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith
6. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
7. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
8. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
9. 9795607 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
10. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
11. 9428509 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
12. 9346812 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
13. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway
14. 8492381 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
15. 8372976 - Methods of treatment comprising the administration of heteroaryl compounds